A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder

Journal of Clinical Psychiatry

Volumn 63, Issue 11, 2002, Pages 1028-1033

  Arnold, Lesley M ^a   McElroy, Susan L ^a   Hudson, James I ^b,c,d   Welge, Jeffrey A ^a   Bennett, Aurora J ^a   Keck Jr , Paul E ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b MCLEAN HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; FLUVOXAMINE MALEATE; PLACEBO; SERTRALINE; SIBUTRAMINE; TOPIRAMATE; VENLAFAXINE;

ADULT; ARTICLE; BINGE EATING DISORDER; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; URINARY FREQUENCY; XEROSTOMIA;

EID: 0036855199     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n1113     Document Type: Article

References (27)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
2. Spitzer RL, Devlin M, Walsh BT, et al. Binge eating disorder: A multisite field trial of the diagnostic criteria. Int J Eat Disord 1992;11:191-203
3. Spitzer RL, Yanovski S, Wadden T, et al. Binge eating disorder: Its further validation in a multisite study. Int J Eat Disord 1993;13:137-153
4. Yanovski SZ, Nelson JE, Dubbert BK, et al. Association of binge eating disorder and psychiatric comorbidity in obese subjects. Am J Psychiatry 1993;150:1472-1479
5. de Zwaan M, Mitchell JE, Raymond NC, et al. Binge eating disorder: Clinical features and treatment of a new diagnosis. Harv Rev Psychiatry 1994;1:310-325
6. Hudson JI, Carter WP, Pope HG Jr. Antidepressant treatment of binge-eating disorder: Research findings and clinical guidelines. J Clin Psychiatry 1996;57(suppl 8):73-79
7. Hudson JI, Pope HG Jr, Carter WP. Pharmacologic therapy of bulimia nervosa. In: Goldstein D, ed. The Management of Eating Disorders and Obesity. Totowa, NJ: Humana Press, Inc; 1999:19-32
8. Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa: A multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry 1992;49:139-147
9. Goldstein DJ, Wilson MG, Thompson VL, et al, and the Fluoxetine Bulimia Nervosa Research Group. Long-term fluoxetine treatment of bulimia nervosa. Br J Psychiatry 1995;166:660-666
10. Hudson JI, McElroy SL, Raymond NC, et al. Fluvoxamine in the treatment of binge-eating disorder: A multicenter, placebo-controlled, double-blind trial. Am J Psychiatry 1998;155:1756-1762
11. McElroy SL, Casuto LS, Nelson EB, et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry 2000;157:1004-1006
12. Metropolitan Life Insurance Company. 1983 Metropolitan height and weight tables. Stat Bull Metrop Life Found 1983;64:3-9
13. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for the DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0). New York, NY: Biometric Research, New York State Psychiatric Institute; 1995
14. Guy W. ECDEU Assessment Manual for Psychopharmacology. US dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
16. Diggle PJ, Liang K, Zeger SL. Analysis of Longitudinal Data. Oxford, UK: Oxford University Press; 1995
17. Gibbons RD, Hedeker D, Elkin I, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Arch Gen Psychiatry 1993;50:739-750
18. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 1997;16:2349-2380
19. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001;11:9-21
20. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. J Clin Psychiatry 2002;63:225-231
21. Monteleone P, Brambilla F, Bortolotti F, et al. Serotonergic dysfunction across the eating disorders: Relationship to eating behaviour, purging behaviour, nutritional status and general psychopathology. Psychol Med 2000;30:1099-1110
22. Kaye W, Gendall K, Strober M. Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biol Psychiatry 1998;44:825-838
23. Appolinario JC, Godoy-Matos A, Fontenelle LF, et al. An open-label trial of sibutramine in obese patients with binge-eating disorder. J Clin Psychiatry 2002;63:28-30
24. Malhotra S, King KH, Welge JA, et al. Venlafaxine treatment of binge-eating disorder associated with obesity: A series of 35 patients. J Clin Psychiatry 2002;63:802-806
25. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: A clinical case series. J Clin Psychiatry 2000;61:368-372
26. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity. Presented at the 53rd Annual Meeting of the American Psychiatric Association Institute on Psychiatric Services; Oct 10-14, 2001; Orlando, Fla
27. Stunkard A, Berkowitz R, Tanrikut C, et al. d-fenfluramine treatment of binge eating disorder. Am J Psychiatry 1996;153:1455-1459